Scientists seek clues in tumors to predict which breast cancers resist standard treatment
NCT ID NCT06361940
Summary
This study aims to learn why some early-stage, hormone-sensitive breast cancers stop responding to standard hormone-blocking drugs. Researchers will give 100 patients hormone therapy for 4-12 weeks before their scheduled surgery and then analyze the removed tumor tissue. By comparing the tumor before and after treatment, they hope to find biological markers that predict treatment resistance and identify new targets for future therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital and the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.